Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma.
作者信息
Lok Anne, Mocquard Julie, Bourcier Jessie, Redelsperger Laurence, Bonnet Antoine, Chauvin Cecile, Thomaré Patrick, Mahé Beatrice, Touzeau Cyrille, Moreau Philippe
出版信息
Haematologica. 2014 Mar;99(3):e33-4. doi: 10.3324/haematol.2013.100396. Epub 2014 Feb 14.
Abstract
摘要
相似文献
1
Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma.
Haematologica. 2014 Mar;99(3):e33-4. doi: 10.3324/haematol.2013.100396. Epub 2014 Feb 14.
2
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.
Blood. 2011 Nov 24;118(22):5752-8; quiz 5982. doi: 10.1182/blood-2011-05-355081. Epub 2011 Aug 17.
3
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
Blood. 2012 Aug 23;120(8):1589-96. doi: 10.1182/blood-2012-02-408922. Epub 2012 Jul 12.
4
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Lancet. 2010 Dec 18;376(9758):2075-85. doi: 10.1016/S0140-6736(10)61424-9. Epub 2010 Dec 9.
5
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Blood. 2012 Jul 5;120(1):9-19. doi: 10.1182/blood-2012-02-408898. Epub 2012 Apr 12.
6
Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
Biol Blood Marrow Transplant. 2012 Mar;18(3):486-92. doi: 10.1016/j.bbmt.2011.12.580. Epub 2011 Dec 22.
7
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
J Clin Oncol. 2012 Jul 10;30(20):2475-82. doi: 10.1200/JCO.2011.37.4918. Epub 2012 May 14.
8
Two cycles of the PS-341/bortezomib, adriamycin, and dexamethasone combination followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.
Eur J Haematol. 2012 Jun;88(6):478-84. doi: 10.1111/j.1600-0609.2012.01771.x. Epub 2012 Apr 11.
9
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma.
Leukemia. 2015 Dec;29(12):2429-31. doi: 10.1038/leu.2015.274. Epub 2015 Oct 7.
10
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
Hematology. 2007 Jun;12(3):235-9. doi: 10.1080/10245330701214236.
引用本文的文献
1
Triplet RVd Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis.
Adv Ther. 2022 Aug;39(8):3799-3834. doi: 10.1007/s12325-022-02195-1. Epub 2022 Jun 30.
2
comparison of the cytotoxic effects of statins on U266 myeloma cell line.
Indian J Med Res. 2019 Dec;150(6):630-634. doi: 10.4103/ijmr.IJMR_672_18.
3
Managing treatment-related peripheral neuropathy in patients with multiple myeloma.
Blood Lymphat Cancer. 2016 Jun 29;6:37-47. doi: 10.2147/BLCTT.S91251. eCollection 2016.
4
Nanotherapeutics for multiple myeloma.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018 Nov;10(6):e1526. doi: 10.1002/wnan.1526. Epub 2018 Apr 26.
5
Spotlight on ixazomib: potential in the treatment of multiple myeloma.
Drug Des Devel Ther. 2016 Jan 11;10:217-26. doi: 10.2147/DDDT.S93602. eCollection 2016.
6
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
Haematologica. 2015 Jul;100(7):964-9. doi: 10.3324/haematol.2015.124347. Epub 2015 Apr 3.
7
Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
Haematologica. 2015 May;100(5):e207-10. doi: 10.3324/haematol.2014.118182. Epub 2015 Jan 16.
8
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma.
Haematologica. 2014 Nov;99(11):e242-3. doi: 10.3324/haematol.2014.110221. Epub 2014 Aug 1.
本文引用的文献
1
Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma.
Oncology. 2013;85(4):223-7. doi: 10.1159/000355197. Epub 2013 Sep 27.
2
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2013 Oct;24 Suppl 6:vi133-7. doi: 10.1093/annonc/mdt297. Epub 2013 Aug 16.
3
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma.
Leukemia. 2013 Nov;27(11):2242-4. doi: 10.1038/leu.2013.101. Epub 2013 Apr 5.
4
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
Blood. 2012 Aug 23;120(8):1589-96. doi: 10.1182/blood-2012-02-408922. Epub 2012 Jul 12.
5
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Blood. 2012 Jul 5;120(1):9-19. doi: 10.1182/blood-2012-02-408898. Epub 2012 Apr 12.
6
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.
Blood. 2011 Nov 24;118(22):5752-8; quiz 5982. doi: 10.1182/blood-2011-05-355081. Epub 2011 Aug 17.
7
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Lancet Oncol. 2011 May;12(5):431-40. doi: 10.1016/S1470-2045(11)70081-X. Epub 2011 Apr 18.
8
Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies.
J Clin Oncol. 2011 May 10;29(14):1898-906. doi: 10.1200/JCO.2010.32.5878. Epub 2011 Apr 11.
9
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Lancet. 2010 Dec 18;376(9758):2075-85. doi: 10.1016/S0140-6736(10)61424-9. Epub 2010 Dec 9.
10
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.
Leukemia. 2009 Jan;23(1):3-9. doi: 10.1038/leu.2008.291. Epub 2008 Oct 30.
Zotero 插件